A new paper co-authored by CEO Henry Skinner and published in the Bulletin of the Atomic Scientists examines the potential impact artificial intelligence and machine learning can have in the fight against antimicrobial resistance. The paper, co-authored by UPenn’s Cesar de la Fuente-Nunez and Dr. Christina Yen of Maine Medical Center, looks at how AI can accelerate drug discovery and improve clinical care. For all the potential benefits of AI, however, the authors note that persistent market challenges and underinvestment into antimicrobial R&D are likely to limit the positive contributions of AI, particularly when it comes to clinical-stage drug development.
Read the full paper here.
